Selective lack of tolerance to delayed gastric emptying after daily administration of WIN 55,212-2 in the rat

Neurogastroenterology and Motility

Volumn 21, Issue 9, 2009, Pages

  Abalo, R ^a   Cabezos, P A ^a   Lopez Miranda V ^a   Vera, G ^a   Gonzalez C ^a   Castillo, M ^a   Fernandez Pujol R ^a   Martin M I ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Cannabinoid; Gastrointestinal motility; Radiology; Rat; Tolerance

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID 1 RECEPTOR ANTAGONIST;

ABDOMINAL RADIOGRAPHY; ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DELAYED GASTRIC EMPTYING; DRUG TOLERANCE; DRUG WITHDRAWAL; FOOD INTAKE; HEART RATE; INTESTINE TRANSIT TIME; MALE; MOTOR PERFORMANCE; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH EMPTYING; STOMACH FUNCTION; STOMACH FUNCTION DISORDER; STOMACH MOTILITY; WEIGHT GAIN;

ANIMALS; BENZOXAZINES; BODY WEIGHT; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; GASTRIC EMPTYING; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRANSIT; MALE; MORPHOLINES; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1;

EID: 68949102282     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2009.01315.x     Document Type: Article

References (61)

1. Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci 2007 9 : 413 30.
2. Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ 2008 178 : 1669 78.
3. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 2007 8 : 885 95.
4. Compton DR, Rice KC, De Costa BR et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993 265 : 218 26.
5. Fox A, Kesingland A, Gentry C et al. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001 92 : 91 100.
6. García MC, Adler-Graschinsky E, Celuch SM. Hypotensive effect of anandamide through the activation of CB1 and VR1 spinal receptors in urethane-anesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 2003 368 : 270 6.
7. Li J, Kaminski NE, Wang DH. Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor. Hypertension 2003 41 : 757 62.
8. Randall MD, Harris D, Kendall DA, Ralevic V. Cardiovascular effects of cannabinoids. Pharmacol Ther 2002 95 : 191 202.
9. Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol 2002 42 : 58S 63S.
10. Sidney S. Cardiovascular consequences of marijuana use. J Clin Pharmacol 2002 42 : 64S 70S.
11. López-Miranda V, Herradon E, Martín MI. Vasorelaxation caused by cannabinoids: mechanisms in different vascular beds. Curr Vasc Pharmacol 2008 6 : 335 46.
12. Chesher GB, Dahl CJ, Everingham M, Jackson DM, Marchant-Williams H, Stammer CA. The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br J Pharmacol 1973 49 : 588 94.
13. Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989 249 : 444 9.
14. Colombo G, Agabio R, Lobina C, Reali R, Gessa GL. Cannabinoid modulation of intestinal propulsion in mice. Eur J Pharmacol 1998 344 : 67 9.
15. Izzo AA, Mascolo N, Capasso R, Germano MP, De Pasquale R, Capasso F. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 1999 360 : 221 3.
16. Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 1999 384 : 37 42.
17. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001 48 : 859 67.
18. Landi M, Croci T, Rinaldi-Carmona M, Maffrand J-P, Le FurG, Manara L. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB1 receptors. Eur J Pharmacol 2002 450 : 77 83.
19. McCallum RW, Soykan I, Sridhar KR, Ricci DA, Lange RC, Plankey MW. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999 13 : 77 80.
20. Esfandyari T, Camilleri M, Ferber I, Burton D, Baxter K, Zinsmeister AR. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil 2006 18 : 831 8.
21. Izzo AA, Pinto L, Borrelli F, Capasso R, Mascolo N, Capasso F. Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol 2000 129 : 1627 32.
22. Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol 1992 105 : 980 4.
23. Pertwee RG, Fernando SR, Nash JE, Coutts AA. Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol 1996 118 : 2199 205.
24. Coutts AA, Pertwee RG. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 1997 121 : 1557 66.
25. Kulkarni-Narla A, Brown DR. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 2000 302 : 73 80.
26. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S. Localisation of cannabinoid CB1 receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 2002 448 : 410 22.
27. Lichtman AH, Martin BR. Cannabinoid tolerance and dependence. Handb Exp Pharmacol 2005 168 : 691 717.
28. Kawasaki H, Watanabe S, Ueki S. Effects of chronic administration of delta-9-tertrahydrocannabinol on the cardiovascular system, and pressor and behavioural responses to brain stimulation in freely moving rats. Eur J Phramacol 1980 65 : 63 9.
29. Adams MD, Chait LD, Earnhardt JT. Tolerance to the cardiovascular effects of delta- 9-tetrahydrocannabinol in the rat. Br J Pharmacol 1976 56 : 43 8.
30. Anderson PF, Jackson DM, Chesher GB, Malor R. Tolerance to the effects of delta 9-tetrahydrocannabinol in mice on intestinal motility, temperature and locomotor activity. Psychopharmacologia 1975 43 : 31 6.
31. Basilico L, Parolaro D, Coleoni M, Costa B, Giagnoni G. Cross-tolerance and convergent dependence between morphine and cannabimimetic agent WIN 55,212-2 in the guinea-pig ileum myenteric plexus. Eur J Pharmacol 1999 376 : 265 71.
32. Guagnini F, Cogliati P, Mukenge S, Ferla G, Croci T. Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips. Br J Pharmacol 2006 148 : 1165 73.
33. Cabezos PA, Vera G, Castillo M, Fernández-Pujol R, Martín MI, Abalo R. Radiological study of gastrointestinal motor activity after acute cisplatin in the rat. Temporal relationship with pica. Auton Neurosci 2008 141 : 54 65.
34. Martín MI, Vera G, Chiarlone A, Cabezos PA, Abalo R. The cannabinoid agonist WIN 55,212-2 prevents the development of mechanical allodynia induced by chronic cisplatin in the rat. Eur J Pain 2006 10 : S58.
35. Vera G, Chiarlone A, Cabezos PA, Pascual D, Martín MI, Abalo R. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci 2007 81 : 468 79.
36. Costa B, Sinicalco D, Trovato AE et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol 2006 14 : 1022 32.
37. Pascual D, Goicoechea C, Suardíaz M, Martín MI. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 2005 118 : 23 34.
38. Masur J, Martz RMW, Korte FJ, Bienik D. Influence of (-) A9-trans-tetrahydrocannabinol and mescaline on the behaviour of rats submitted to food competition situations. Psychopharmacologia 1971 22 : 187 94.
39. Drew WG, Miller LL, Wikler A. Effects of ‡9-THC on the open-field activity of the rat. Psychopharmacologia 1972 23 : 289 99.
40. Dewey WL, Harris LS, Kennedy JS. Some pharmacological and toxicological effects of I-trans-A8 and 1-trans-A9-tetrahydrocannabinol in laboratory rodents. Archs ilt Pharmacodwi Ther 1972 196 : 133 45.
41. Hillard CJ. Endocannabinoids and vascular function. J Pharmacol Exp Ther 2000 29 : 27 32.
42. Szabo B, Schlicker E. Effects of cannabinoids on neurotransmission. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology. Heidelberg : Springer-Verlag, 2005 : 327 65.
43. Perez-Reyes M, White WR, McDonald SA, Hicks RE, Jeffcoat AR, Cook CE. The pharmacologic effects of daily marijuana smoking in humans. Pharmacol Biochem Behav 1991 40 : 691 4.
44. Perron RR, Tyson RL, Sutherland GR. Delta9 -tetrahydrocannabinol increases brain temperature and inverts circadian rhythms. Neuroreport 2001 12 : 3791 4.
45. Oviedo A, Glowa J, Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 1993 616 : 293 302.
46. Whitlow CT, Freedland CS, Porrino LJ. Functional consequences of the repeated administration of Delta9-tetrahydrocannabinol in the rat. Drug Alcohol Depend 2003 71 : 169 77.
47. Aceto MD, Scates SM, Martin BB. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. Eur J Pharmacol 2001 416 : 75 81.
48. Giuliani D, Ottani A, Ferrari F. Effects of the cannabinoid receptor agonist, HU 210, on ingestive behaviour and body weight of rats. Eur J Pharmacol 2000 391 : 275 9.
49. Dalton VS, Wang H, Zavitsanou K. HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochem Res 2009 44. DOI :.
50. Page ME, Oropeza VC, Sparks SE, Qian Y, Menko AS, Van Bockstaele EJ. Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacol Biochem Behav 2007 86 : 162 8.
51. Krowicki ZK, Moerschbaecher JM, Winsauer PJ, Digavalli SV, Hornby PJ. Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur J Pharmacol 1999 371 : 187 96.
52. Izzo AA, Mascolo N, Borrelli F, Capasso F. Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. Br J Pharmacol 1998 124 : 1363 8.
53. Heinemann A, Shahbazian A, Holzer P. Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology 1999 38 : 1289 97.
54. Izzo AA, Mascolo N, Tonini M, Capasso F. Modulation of peristalsis by cannabinoid CB(1) ligands in the isolated guinea-pig ileum. Br J Pharmacol 2000 129 : 984 90.
55. Baldassano S, Serio R, Mule' F. Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle. Eur J Pharmacol 2008 582 : 132 8.
56. Abalo R, Rivera AJ, Vera G, Suardíaz M, Martín MI. Evaluation of the effect of age on cannabinoid receptor functionality and expression in guinea-pig ileum longitudinal muscle-myenteric plexus preparations. Neurosci Lett 2005 383 : 176 81.
57. Van Sickle MD, Duncan M, Kingsley PJ et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005 310 : 329 32.
58. Duncan M, Mouihate A, Mackie K et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 2008 295 : G78 87.
59. Pertwee RG. Inverse agonism and neutral antagonism at cananbinoid CB1 receptor. Life Sci 2005 76 : 1307 24.
60. Calignano A, La Rana G, Makriyannis A, Lin SY, Beltramo M, Piomelli D. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur J Pharmacol 1997 340 : R7 8.
61. Pinto L, Izzo AA, Cascio MG et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002 123 : 227 34.